Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed Stage IIIB or IV non-resectable NSCLC. Recurrent disease after resection for earlier stage disease is acceptable as long as patients are at least 6 months from surgery.~* Treatment plan includes a platinum-based doublet chemotherapy.~* ECOG 0, 1 or 2.~* Self-reported loss of body weight or anorexia.~* Serum C-reactive protein ≥5 mg/L.~* Life expectancy of at least 6 months.~* Adequate bone marrow, liver and renal function.~* Normal serum potassium.~* Ability to comply with the study requirements and give written informed consent.~Exclusion Criteria:~* Known physical or functional obstruction of the gastrointestinal tract, malabsorption, intractable vomiting, uncontrollable diarrhea, concurrently receiving tube feeding or parenteral nutrition, or unable to swallow investigational drug product.~* Concomitant therapy with an appetite stimulant.~* History of poorly controlled hypertension or congestive heart failure.~* Any implanted devices that could interfere with DXA scanning.~* Prolongation of QT interval.~* History of additional risk factors for torsades de pointe.~* Concomitant therapy with beta-adrenergic receptor antagonists (beta-blockers) or ergot derivatives.~* Females who are breast feeding, pregnant or of child-bearing potential who are not using adequate birth control.~* Any second malignancy which might confound the interpretation of safety or efficacy assessments.~* Any condition which increases the patient's risk for participating in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).